Apollomics, Inc. (NASDAQ:APLM) Short Interest Update

Apollomics, Inc. (NASDAQ:APLM) saw a significant increase in short interest in June. As of June 30th, there was short interest totalling 177,100 shares, an increase of 120.8% from the June 15th total of 80,200 shares. Currently, 0.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 386,300 shares, the short-interest ratio is currently 0.5 days.

Institutional Trading of Apollomics

A hedge fund recently bought a new stake in Apollomics stock. Powell Investment Advisors LLC bought a new position in shares of Apollomics, Inc. (NASDAQ:APLM) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 130,297 shares of the company’s stock, valued at approximately $98,000. Powell Investment Advisors LLC owned about 0.15% of Apollomics at the end of the most recent reporting period. Hedge funds and other institutional investors own 19.13% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lowered their price objective on Apollomics from $5.00 to $2.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th.

Apollomics Stock Down 3.2 %

APLM opened at $0.20 on Friday. Apollomics has a twelve month low of $0.18 and a twelve month high of $6.20. The company has a 50-day simple moving average of $0.26 and a 200 day simple moving average of $0.54.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.